Sonic Healthcare (SKHHY) Earnings Dates, Call Summary & Reports

Compare

19 Followers

Earnings Data

Report Date

Aug 26, 2026

TBA (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

0.48

Last Year’s EPS

0.37

Same Quarter Last Year

Analyst Consensus

―

Based on 0 Analysts Ratings

Earnings Call Summary

Q2 2026

Earnings Call Date:Feb 18, 2026|

% Change Since:

Earnings Call Sentiment|Positive

Overall the call presents a largely positive operational and financial picture: strong H1 results (revenue, EBITDA, net profit), maintained full-year EBITDA guidance, margin improvement at group level (+30 bps), successful integration progress in major acquisitions (Germany LADR and Swiss deals), and continued organic growth across several markets (Australia, Germany, UK, Radiology). Offsetting these positives are concentrated challenges in the U.S. (margin pressure, restructuring and delayed revenue collection benefits), elevated short-term net debt and working capital due to acquisitions and the Change Healthcare billing disruption, FX headwinds for H2, and some regulatory/wage uncertainties (Germany GOA reform and Australian Fair Work outcomes). Management has clear remediation and capital management plans (operating review, sale-and-leaseback program, potential buybacks) and has retained guidance, supporting a constructive outlook despite identifiable near-term risks.

Company Guidance

Sonic reaffirmed full‑year adjusted EBITDA guidance of AUD 1.87–1.95 billion (constant currency) after reporting H1 revenue of AUD 5.445 billion, EBITDA of AUD 907 million, net profit of AUD 262 million and EPS of AUD 0.531; management said group organic growth is running at c.5% and adjusted EBITDA margins were up ~30 basis points year‑on‑year (H1), with H1 acquisition costs of AUD 8 million. For the full year depreciation is now guided to AUD 770–780 million (constant currency), interest expense is expected to increase ~15% (constant currency) versus last year, and the effective tax rate is guided at 27%; the guidance assumes completed acquisitions only, current interest rates, and excludes any gains from property sales. Capital management priorities remain an investment‑grade balance sheet (debt cover ~2.5x), a progressive interim dividend of AUD 0.45 (up 2.3%, 60% franked; record 5 Mar, pay 19 Mar), available headroom ~AUD 1.0 billion pre‑dividend, potential sale‑and‑leaseback transactions (Brisbane hub targeted June 2026) with proceeds possibly funding on‑market buybacks, and near‑term capex for Docklands of c. AUD 20–30 million over the next six months (maintenance capex ~3–3.5% of revenue); FX provided a strong H1 tailwind and is still expected to be a net tailwind for the year but more modest if current rates prevail.

Strong H1 Financial Results

Revenue of $5.445 billion, EBITDA of $907 million, net profit of $262 million and EPS of AUD 0.531 for H1 FY2026.

Organic Revenue Growth

Group organic revenue growth of 5% in H1 FY2026, reflecting broad-based underlying demand across key markets.

Adjusted EBITDA Margin Expansion

Adjusted EBITDA margins improved by c.30 basis points year-on-year (H1 2025 to H1 2026) after accounting for acquisition costs and other one-offs.

Germany: Strong Revenue Growth and Integration Progress

Germany achieved 40% revenue growth on a constant currency basis (organic growth ~5%). LADR acquisition settled 1 July and integration is progressing across 16 work streams with expected synergy capture and margin expansion.

United Kingdom Contract Wins and Growth

UK delivered organic growth of 24% driven by the Hertfordshire & West Essex (HWE) NHS contract; new hub lab in Watford to go live in July to service HWE.

Australia: Solid Pathology Performance

Australian Pathology achieved 5% organic growth; Medicare indexation of 2.4% applied to ~30% of schedule fees; successful private billing rollouts for selected tests and new services commenced at Hollywood Private Hospital (Perth).

Radiology and Clinical Services Momentum

Radiology organic revenue growth of 7% (EBITDA growth normalized +5%); Sonic Clinical Services revenue +5% and EBITDA +20% (off a low base) following integration of National Skin Cancer Clinics.

Advanced Diagnostics Expansion

Advanced diagnostics combining Cairo Diagnostics and ThyroSeq maturing into a nationwide offering; digital pathology rollout progressing with >60% dermatopathology volume on proprietary platform (PathologyWatch).

Capital Management and Dividend

Interim dividend increased 2.3% to AUD 0.45 (60% franked); capital priorities include maintaining investment-grade balance sheet, progressive dividends (medium-term payout target 70%-80%), selective acquisitions and potential share buybacks funded by property sales.

Balance Sheet Headroom and Guidance Maintained

Debt cover ratio at historic levels of 2.5x; available headroom of approximately $1.0 billion (pre-interim dividend); company reaffirmed constant-currency EBITDA guidance of $1.87–$1.95 billion and reduced depreciation guidance to $770–$780 million.

Active Property Monetisation Program

Sale and leaseback process launched for major Brisbane hub (Bowen Hills) targeting June 2026 completion with expected gain on sale; other sale-and-leaseback opportunities under consideration to fund potential buybacks.

Sonic Healthcare (SKHHY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SKHHY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 26, 2026	2026 (Q4)	0.47 / -	0.37	―	―	―
Feb 18, 2026	2026 (Q2)	0.36 / 0.35	0.315	12.06% (+0.04)
Aug 20, 2025	2025 (Q4)	0.39 / 0.37	0.401	-7.73% (-0.03)
Feb 19, 2025	2025 (Q2)	0.32 / 0.32	0.28	12.50% (+0.03)
Aug 21, 2024	2024 (Q4)	0.40 / 0.40	0.436	-8.03% (-0.03)
Feb 19, 2024	2024 (Q2)	0.42 / 0.28	0.556	-49.64% (-0.28)
Aug 17, 2023	2023 (Q4)	0.49 / 0.44	0.913	-52.25% (-0.48)
Feb 15, 2023	2023 (Q2)	0.57 / 0.56	1.232	-54.87% (-0.68)
Aug 23, 2022	2022 (Q4)	0.78 / 0.91	0.964	-5.29% (-0.05)	―	―
Feb 20, 2022	2022 (Q2)	1.30 / 1.23	1.101	11.90% (+0.13)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SKHHY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 18, 2026	$15.02	$16.47	+9.65%
Aug 20, 2025	$18.03	$15.70	-12.90%
Feb 19, 2025	$17.61	$17.25	-2.04%
Aug 21, 2024	$17.58	$17.66	+0.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sonic Healthcare Limited (SKHHY) report earnings?

Sonic Healthcare Limited (SKHHY) is schdueled to report earning on Aug 26, 2026, TBA (Confirmed).

What is Sonic Healthcare Limited (SKHHY) earnings time?

Sonic Healthcare Limited (SKHHY) earnings time is at Aug 26, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SKHHY EPS forecast?

SKHHY EPS forecast for the fiscal quarter 2026 (Q4) is 0.48.